Ann: June 2017 Quarterly Report, page-4

Some things in this announcement are really good and probably not priced. For example, the fact they imply they'll research specific formulations and manufacture with their production/ GMP manufacturing partners.

Breast cancer requires a specific formulation but they have some of the leading experts on the subject.

This field is a gold mine because most advanced studies are only done to prove a pre-determined outcome.

This is a pharma stock without the risk, potential integrated model evolution and many exit strategies...